CVG Stock Overview An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
CSPC Pharmaceutical Group Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for CSPC Pharmaceutical Group Historical stock prices Current Share Price HK$0.58 52 Week High HK$0.95 52 Week Low HK$0.51 Beta 0.64 1 Month Change -7.28% 3 Month Change -5.63% 1 Year Change -27.43% 3 Year Change -38.89% 5 Year Change -47.46% Change since IPO 1,014.38%
Recent News & Updates CSPC Pharmaceutical Group Limited Announces SYS6005 (Antibody-Drug Conjugate) Obtains Clinical Trial Approval
CSPC Pharmaceutical Group Limited Announces Board Changes Dec 06
Third quarter 2024 earnings released: EPS: CN¥0.065 (vs CN¥0.13 in 3Q 2023) Nov 17
CSPC Pharmaceutical Group Limited to Report Nine Months, 2024 Results on Nov 15, 2024 Nov 06
Upcoming dividend of HK$0.16 per share Oct 24 CSPC Pharmaceutical Group Limited Announces Omalizumab for Injection Obtains Marketing Approval from NMPA See more updates CSPC Pharmaceutical Group Limited Announces SYS6005 (Antibody-Drug Conjugate) Obtains Clinical Trial Approval
CSPC Pharmaceutical Group Limited Announces Board Changes Dec 06
Third quarter 2024 earnings released: EPS: CN¥0.065 (vs CN¥0.13 in 3Q 2023) Nov 17
CSPC Pharmaceutical Group Limited to Report Nine Months, 2024 Results on Nov 15, 2024 Nov 06
Upcoming dividend of HK$0.16 per share Oct 24 CSPC Pharmaceutical Group Limited Announces Omalizumab for Injection Obtains Marketing Approval from NMPA
Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 2Q 2023) Sep 21
CSPC Pharmaceutical Group Limited Announces Valsartan Levoamlodipine Maleate Tablets Obtains Clinical Trial Approval Sep 20 CSPC Pharmaceutical Group Limited (SEHK:1093) announces an Equity Buyback for HKD 5,000 million worth of its shares. Sep 19
Executive Chairman recently bought €536k worth of stock Sep 10 CSPC Pharmaceutical Group Limited Announces Aprepitant Injection Obtains Drug Registration Approval
Executive Chairman recently bought €776k worth of stock Aug 25
Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 2Q 2023) Aug 22
CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2024, Payable on 20 November 2024 Aug 21
CSPC Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024 Aug 09
CSPC Pharmaceutical Group Limited Obtains Approval from the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Jul 11 CSPC Pharmaceutical Group Limited Announces Enlonstobart Injection Obtains Conditional Marketing Approval
CSPC Pharmaceutical Group Limited Obtains Approval from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Jun 25 CSPC Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2023
First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 1Q 2023) May 28
Upcoming dividend of HK$0.14 per share May 24
CSPC Pharmaceutical Group Limited Announces Recombinant Fully Human Anti-bKlotho Monoclonal Antibody Drug (JMT202) Obtains Approval from National Medical Products Administration of the People's Republic of China May 18
CSPC Pharmaceutical Group Limited to Report Q1, 2024 Results on May 27, 2024 May 16
Cspc Pharmaceutical Group Limited Announces That the Peramivir Injection (15Ml:0.15G) (The "Product") Developed by the Group Has Obtained Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China, and Is Deemed to Have Passed the Consistency Evaluation of Quality and Efficacy for Generic Drugs May 15
CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023 Apr 28
CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor (SYH2039) Obtains Clinical Trial Approval in the U.S Apr 27
Full year 2023 earnings released: EPS: CN¥0.49 (vs CN¥0.51 in FY 2022) Apr 26
CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval Mar 23
Final dividend of HK$0.14 announced Mar 22 CSPC Pharmaceutical Group Limited, Annual General Meeting, May 28, 2024
Full year 2023 earnings released: EPS: CN¥0.49 (vs CN¥0.51 in FY 2022) Mar 20
CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024 Mar 20
CSPC Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024 Mar 09
CSPC Pharmaceutical Group Limited's Bispecific Fusion Protein Drug JMT106 Obtains Clinical Trial Approval from the U.S. Food and Drug Administration Jan 15
CSPC Pharmaceutical Group Limited Announces Submission of New Drug Application for Irinotecan Liposome Injection to U.S. FDA Dec 18
CSPC Pharmaceutical Group Limited Obtains Approval for Dextromethorphan Hydrobromide and Quinidine Sulphate Orally Disintegrating Tablets Dec 12
CSPC Pharmaceutical Group Limited Announces Bivalent Covid-19 MRNA Vaccine (SYS6006.32) Included for Emergency Use in China Dec 02
Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.13 in 3Q 2022) Dec 01
CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Nov 29
CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Nov 28
CSPC Pharmaceutical Group Limited to Report Nine Months, 2023 Results on Nov 30, 2023 Nov 21
CSPC Pharmaceutical Group Limited's ALMB-0166 Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Phase II Clinical Trial Evaluating its Efficacy and Safety in Patients with Acute Ischemic Stroke in China Nov 18
Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE Nov 08
CSPC Pharmaceutical Group Limited Obtains Approval Granted by the National Medical Products Administration of the People's Republic of China Nov 04
CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Oct 31
CSPC Pharmaceutical Group Limited Announces NBL-028 for the Treatment of Advanced Tumors Oct 26
CSPC Pharmaceutical Group Limited Announces Biologic License Application Approval for Narlumosbart for Injection (JMT103) by the NMPA Sep 07
Upcoming dividend of HK$0.14 per share at 4.7% yield Aug 31
CSPC Pharmaceutical Group Limited Announces Semaglutide Injection Obtains Clinical Trial Approval Aug 30
New major risk - Revenue and earnings growth Aug 28
CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China Aug 25
CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2023, Payable on 12 October 2023 Aug 24
Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.13 in 2Q 2022) Aug 23
New minor risk - Share price stability Aug 15
CSPC Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 23, 2023 Aug 12
Cspc Pharmaceutical Group Limited Announces Biologic License Application of Batoclimab (Hbm9161) Jun 30
CSPC Ouyi Pharmaceutical Co., Ltd. Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China Jun 27 CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China
Cspc Pharmaceutical Group Limited Announces That Clinical Trial Application for Cpo301 Jun 09
Elevation Oncology Inc. Together with CSPC Pharmaceutical Group Limited Announce Promising Initial Clinical Data for SYSA1801 (EO-3021) from the Ongoing Phase 1 Dose Escalation and Expansion Study in China Jun 07
Elevation Oncology Highlights First-In-Human Phase 1 Sysa1801 (Eo-3021) Clinical Data to Be Presented by Partner Cspc Pharmaceutical Group Limited At Asco 2023 Jun 06
CSPC Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2022 Jun 01
Upcoming dividend of HK$0.11 per share at 2.9% yield May 29
First quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.12 in 1Q 2022) May 28
CSPC Pharmaceutical Group Limited to Report Q1, 2023 Results on May 25, 2023 May 17
Executive Chairman recently bought €1.5m worth of stock Mar 30
Full year 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.47 in FY 2021) Mar 23
CSPC Pharmaceutical Group Limited Announces Highly Selective PRMT5 Inhibitor SYH2045 Obtains Clinical Trial Approval Jan 05
Cspc Pharmaceutical Group Limited Announces ALMB-0166 for the Treatment of Osteoarthritis Obtains Clinical Trial Approval Dec 31
CSPC Pharmaceutical Group Limited Receives Approval for SYH2043 from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Dec 30
CSPC Pharmaceutical Group Limited Announces NBL-020 for the Treatment of Advanced Solid Tumors Obtains Clinical Trial Approval in the U.S Dec 23 Cspc Pharmaceutical Group Limited Announces That Syh2055 Developed by the Group Has Obtained Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Dec 08
CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate CPO204 Obtains Clinical Trial Approval in the U.S Nov 30
Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.11 in 3Q 2021) Nov 24
CSPC Pharmaceutical Group Limited's SYHX1901 Tablets Obtains Approval Granted by the National Medical Products Administration Nov 24
CSPC Pharmaceutical Group Limited Announces New Indication Application for Marketing Approval of Mingfule Nov 17
CSPC Pharmaceutical Group Limited to Report Nine Months, 2022 Results on Nov 23, 2022 Nov 12
CSPC Pharmaceutical Group Limited Appoints Li Quan as an Independent Non-Executive Director Nov 09
Investor sentiment improved over the past week Nov 03
CSPC Pharmaceutical Group Limited Announces the Antibody-Drug Conjugate Sys6002 Oct 28
CSPC Pharmaceutical Group Limited Announces TG103 Injection Obtains Clinical Trial Approval for the Treatment of Non-Alcoholic Steatohepatitis Sep 10
Upcoming dividend of HK$0.10 per share Sep 01
Second quarter 2022 earnings released Aug 25
CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2022, Payable on 11 October 2022 Aug 25
CSPC Pharmaceutical Group Limited Announces Completion of Clinical Study of Heterologous Booster Immunization of SARS-CoV-2 mRNA Vaccine Aug 24
Cspc Pharmaceutical Group Limited Announces Selective Ntrk and Ros1 Dual Inhibitor Syhx2009 Obtains Clinical Trial Approval Aug 23
CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China Aug 20 Shareholder Returns CVG DE Pharmaceuticals DE Market 7D 0.07% -2.2% -2.0% 1Y -27.4% -15.8% 6.8%
See full shareholder returns
Return vs Market: CVG underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is CVG's price volatile compared to industry and market? CVG volatility CVG Average Weekly Movement 10.9% Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.4% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: CVG's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CVG's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer.
Show more CSPC Pharmaceutical Group Limited Fundamentals Summary How do CSPC Pharmaceutical Group's earnings and revenue compare to its market cap? CVG fundamental statistics Market cap €6.89b Earnings (TTM ) €678.94m Revenue (TTM ) €3.99b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CVG income statement (TTM ) Revenue CN¥30.27b Cost of Revenue CN¥8.90b Gross Profit CN¥21.37b Other Expenses CN¥16.21b Earnings CN¥5.16b
Dividends
6.6% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 02:09 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources CSPC Pharmaceutical Group Limited is covered by 50 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Wai Chak Yuen BOCI Research Ltd. Sharon Shi BOCI Research Ltd. Ethan Cui BofA Global Research
Show 47 more analysts 
